Literature DB >> 16778412

Bucillamine-induced pemphigus vulgaris in a patient with rheumatoid arthritis and polymyositis overlap syndrome.

Jin-Wuk Hur1, Chang-Woo Lee, Dae-Hyun Yoo.   

Abstract

Bucillamine is a disease modifying anti-rheumatic drug, structurally similar to D-penicillamine. Although D-penicillamine-induced pemphigus has been not infrequently demonstrated, pemphigus associated with bucillamine was rarely reported. We describe a patient complicating pemphigus vulgaris after bucillamine treatment in rheumatoid arthritis (RA) and polymyositis (PM) overlap syndrome. PM and RA overlap syndrome was diagnosed three years ago and bucillamine was administrated for 20 months. Skin lesions including erythematous flaccid blisters on her chest, axillae, and back were occurred and were compatible with pemphigus vulgaris by typical pathology. Withdrawal from bucillamine and prednisolone treatment made rapid improvement of pemphigus lesions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16778412      PMCID: PMC2729974          DOI: 10.3346/jkms.2006.21.3.585

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  16 in total

1.  Drug-induced pemphigus foliaceus with features of pemphigus vulgaris.

Authors:  K Ogata; H Nakajima; M Ikeda; Y Yamamoto; M Amagai; T Hashimoto; H Kodama
Journal:  Br J Dermatol       Date:  2001-02       Impact factor: 9.302

Review 2.  Current and prospective understanding of clinical classification, pathomechanisms and therapy in pemphigus.

Authors:  Yasuo Kitajima
Journal:  Arch Dermatol Res       Date:  2003-01-15       Impact factor: 3.017

3.  [Lung injury associated with bucillamine therapy].

Authors:  M Negishi; S Kaga; T Kasama; M Hashimoto; T Fukushima; N Yamagata; M Tabata; K Kobayashi; H Ide; T Takahashi
Journal:  Ryumachi       Date:  1992-04

4.  Pemphigus vulgaris induced by D-penicillamine therapy in a patient with systemic sclerosis.

Authors:  M Shapiro; S Jimenez; V P Werth
Journal:  J Am Acad Dermatol       Date:  2000-02       Impact factor: 11.527

5.  [A case of rheumatoid arthritis with bucillamine-induced myasthenia gravis treated by immunoadsorption therapy].

Authors:  N Sawa; Y Ubara; S Hara; K Hideyuki; T Tagami; K Yokoyama; F Takemoto; A Yamada; T Mori; A Mikami; S Tachibana; K Nakase
Journal:  Ryumachi       Date:  1999-02

6.  Treatment of pemphigus.

Authors:  T Piamphongsant; S Ophaswongse
Journal:  Int J Dermatol       Date:  1991-02       Impact factor: 2.736

7.  D-Penicillamine--induced pemphigus syndrome.

Authors:  C W Yung; G W Hambrick
Journal:  J Am Acad Dermatol       Date:  1982-03       Impact factor: 11.527

Review 8.  Penicillamine induced pemphigus.

Authors:  V C Ho; H B Stein; R A Ongley; W A McLeod
Journal:  J Rheumatol       Date:  1985-06       Impact factor: 4.666

Review 9.  Penicillamine: review and cutaneous manifestations.

Authors:  R S Levy; M Fisher; J N Alter
Journal:  J Am Acad Dermatol       Date:  1983-04       Impact factor: 11.527

10.  Clinical course of bucillamine-induced nephropathy in patients with rheumatoid arthritis.

Authors:  Mie Obayashi; Takashi Uzu; Tamaki Harada; Masafumi Yamato; Ken Takahara; Atsushi Yamauchi
Journal:  Clin Exp Nephrol       Date:  2003-12       Impact factor: 2.801

View more
  1 in total

1.  Pemphigus Vulgaris Associated with Rheumatoid Arthritis in a Patient not Taking Penicillamine.

Authors:  Narges Gholizadeh; Ali Taghavi Zenouz; Hossein Eslami
Journal:  J Dent Res Dent Clin Dent Prospects       Date:  2012-03-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.